Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E J Demant

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Cancer Communications|January 1, 1990
The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumorE Friche, P B Jensen, M Sehested, et al.
British Journal of Cancer|July 1, 1990
Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cellsM Sehested, T Skovsgaard, P B Jensen, et al.
Biochemical Pharmacology|August 3, 1993
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16)M Sehested, P B Jensen, B S Sørensen, et al.
British Journal of Cancer|December 1, 1989
Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulatorsM Sehested, P B Jensen, T Skovsgaard, et al.
Cancer Research|June 1, 1994
Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environmentsP B Jensen, B S Sørensen, M Sehested, et al.
British Journal of Cancer|December 1, 1989
In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL)P B Jensen, L Vindeløv, H Roed, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivityP B Jensen, H Roed, M Sehested, et al.
Biochemical Pharmacology|May 25, 1993
Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistanceP B Jensen, B S Sørensen, M Sehested, et al.
Cancer Research|June 1, 1990
Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavageP B Jensen, B S Sørensen, E J Demant, et al.
The Journal of Biological Chemistry|June 5, 2001
Lipid rafts exist as stable cholesterol-independent microdomains in the brush border membrane of enterocytesG H Hansen, L Immerdal, E Thorsen, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Cancer Communications|January 1, 1990
The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumorE Friche, P B Jensen, M Sehested, et al.
British Journal of Cancer|July 1, 1990
Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cellsM Sehested, T Skovsgaard, P B Jensen, et al.
Biochemical Pharmacology|August 3, 1993
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16)M Sehested, P B Jensen, B S Sørensen, et al.
British Journal of Cancer|December 1, 1989
Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulatorsM Sehested, P B Jensen, T Skovsgaard, et al.
Cancer Research|June 1, 1994
Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environmentsP B Jensen, B S Sørensen, M Sehested, et al.
British Journal of Cancer|December 1, 1989
In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL)P B Jensen, L Vindeløv, H Roed, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivityP B Jensen, H Roed, M Sehested, et al.
Biochemical Pharmacology|May 25, 1993
Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistanceP B Jensen, B S Sørensen, M Sehested, et al.
Cancer Research|June 1, 1990
Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavageP B Jensen, B S Sørensen, E J Demant, et al.
The Journal of Biological Chemistry|June 5, 2001
Lipid rafts exist as stable cholesterol-independent microdomains in the brush border membrane of enterocytesG H Hansen, L Immerdal, E Thorsen, et al.
Pageof 5